What are you looking for?
Need help finding what you are looking for? Contact Us

PUBLISHER: Mordor Intelligence | PRODUCT CODE: 1197920

Cover Image

PUBLISHER: Mordor Intelligence | PRODUCT CODE: 1197920

Peptide Therapeutics Market - Growth, Trends, and Forecasts (2023 - 2028)

PAGES: 133 Pages
DELIVERY TIME: 2-3 business days
PDF (Single User License)
USD 4750
PDF (Team License: Up to 7 Users)
USD 5250
PDF (Site License)
USD 6500
PDF (Corporate License)
USD 8750

Add to Cart

The peptide therapeutics market was valued at approximately USD 28,510.60 million in 2020, and it is expected to register a CAGR of 9.66% over the forecast period.

Novel peptides are being developed and repurposed as therapeutics for the treatment of COVID-19. Globally, researchers continue to search for compounds that either block the mechanisms important for SARS-CoV-2 infection and replication or treat conditions caused by the infection. On February 21, 2020, the FDA updated its definition of a biologic to include chemically synthesized polypeptides greater than 40 amino acids but less than 100 amino acids in size (synthetic proteins) and synthetic peptides 40 amino acids or less. As of May 2020, there were 21 peptide drugs for the treatment of COVID-19, including 15 synthetic peptides in development for the treatment of acute respiratory distress syndrome (ARDS) and other respiratory illnesses caused by SARS-Cov-2 infection. Hence, COVID-19 may have a positive impact on the peptide therapeutics market as peptide drugs are being considered as a treatment option for dealing with COVID-19. However, the current applications of peptide therapeutics in oncology, metabolic disorders, etc., have been disrupted due to a shortage of drugs and supply chain issues, along with the slow progress of clinical trials related to non-COVID-19 therapeutics.

The major factors driving the market growth are the increasing prevalence of cancer and metabolic disorders, rising investments in research and development of novel drugs, and technological advancements in peptide therapeutics. According to the World Health Organization (WHO), chronic diseases, such as cancer, cardiovascular diseases, and diabetes, are the leading causes of death and disability worldwide. Disease rates from chronic conditions are accelerating globally, advancing across every region and pervading all socioeconomic classes. In 2020, the contribution of chronic diseases was estimated to have caused 73% of all deaths and 60% of the global burden of diseases. Thus, the increasing incidence of chronic diseases accelerates the need for effective therapeutics, which in turn, is expected to drive the growth of the peptide therapeutics market. However, instability issues of peptide therapeutics, the high cost of developing drugs, and stringent regulatory requirements for drug approval are expected to restrain the market growth.

Peptide Therapeutics Market Trends

The Cancer Segment is Expected to Register the Highest CAGR Over the Forecast Period

Peptides offer favorable prospects in targeted drug delivery for cancer due to their high specificity, discernment, small sizes, ease of modification, and high biocompatibility. The increasing frequency of cancer globally and increasing prescription of peptide therapeutics for cancer treatment are the key factors responsible for the dominance of this segment.

According to the International Agency Research on Cancer- GLOBOCAN 2020 report, a total of 19,292,789 new cancer cases were diagnosed worldwide in 2020, with 9,958,133 deaths due to cancer. Also, the five-year prevalent cases of cancer were estimated to be 50,550,287 globally. The number of new cancer cases is expected to reach 28,887,940 by 2040 worldwide. Thus, the high prevalence of cancer cases globally is expected to play a vital role in the growth of the studied segment over the forecast period. Furthermore, rising awareness among patients and healthcare professionals regarding the adverse effects of chemotherapy and radiation therapy is a major factor for the growing focus on alternative therapeutics such as peptide-based drugs.

However, according to the research article published in Nature Cancer, 2020, the COVID-19 pandemic is expected to have disrupted the spectrum of cancer care, including delayed diagnoses, treatment, and halting clinical trials aimed at developing efficient therapeutics for cancer treatment, within which peptide therapeutics for cancer treatment is of no exception. Hence, the studied segment is predicted to be significantly impacted due to the pandemic.

North America Dominates the Market, and It is Expected to do Same during the Forecast Period

North America is expected to dominate the overall market throughout the forecast period. The market growth is due to factors such as a rise in awareness levels relating to peptide therapeutic products, the increasing necessity for diagnostics in cancer and other diseases, and the growing biotechnology industry.

The increasing research and development expenditure by governments and key players is also expected to help peptide therapeutics sustain dominance over the coming years. A properly established biopharmaceutical and pharmaceutical industry in this region is a major factor responsible for growth. In the North American region, the United States holds the largest market share due to factors such as the increasing number of research programs in the medical industry and the growing number of diseases in the country, which is anticipated to stimulate the demand in this region. According to the estimates of the American Cancer Society, in 2020, an estimated 1.8 million new cancer cases were diagnosed, and 606,520 cancer deaths were reported in the United States. Owing to the increasing burden of cancer, the demand for peptide therapeutics is expected to grow. Hence, given the aforementioned factors, the peptide therapeutics market is expected to witness significant growth in North America over the forecast period.

However, according to the research article published in Applied Clinical Trials, in October 2020, the COVID-19 pandemic caused major disruptions to clinical trial execution in the United States, impacting key stakeholders across the healthcare industry. The sponsors, CROs, and other organizations that support drug development shifted to remote working environments, and an estimated 80% of non-COVID-19 trials were stopped or interrupted as a result of the COVID-19 pandemic. Hence, COVID-19 is expected to have a significant impact on the non-COVID-19 peptide therapeutics market in the region during the pandemic.

Peptide Therapeutics Market Competitor Analysis

The peptide therapeutics market is moderately competitive and consists of several major players. Some of the companies currently dominating the market are Eli Lilly and Company, Pfizer Inc., Amgen Inc., Bristol-Myers Squibb Company, EVER NEURO PHARMA GmbH, Takeda Pharmaceutical Company Limited, and many others. The major players are involved in strategic alliances such as acquisitions and collaborations, along with research activities, for the global expansion of their product portfolios.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Product Code: 67574



  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Cancer and Metabolic Disorders
    • 4.2.2 Rising Investments in Research and Development of Novel Drugs
    • 4.2.3 Technological Advancements
  • 4.3 Market Restraints
    • 4.3.1 Instability of Peptides
    • 4.3.2 High Cost of Developing Drugs and Stringent Regulatory Requirements for Drug Approval​
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD Million)

  • 5.1 Marketing Type
    • 5.1.1 Generic
    • 5.1.2 Branded
  • 5.2 Application
    • 5.2.1 Gastrointestinal Disorders
    • 5.2.2 Neurological Disorders
    • 5.2.3 Metabolic Disorders
    • 5.2.4 Cancer
    • 5.2.5 Other Applications
  • 5.3 Route of Administration
    • 5.3.1 Parenteral
    • 5.3.2 Oral
    • 5.3.3 Other Routes of Administration
  • 5.4 Geography
    • 5.4.1 North America
      • United States
      • Canada
      • Mexico
    • 5.4.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.4.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.4.4 Middle-East
      • GCC
      • South Africa
      • Rest of Middle-East
    • 5.4.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 Eli Lilly and Company
    • 6.1.2 Amgen Inc.
    • 6.1.3 Pfizer Inc.
    • 6.1.4 Bristol-Myers Squibb Company
    • 6.1.5 Ever Neuro Pharma GmbH
    • 6.1.6 Takeda Pharmaceutical Company Limited
    • 6.1.7 Teva Pharmaceuticals Industries Ltd
    • 6.1.8 AstraZeneca PLC
    • 6.1.9 GlaxoSmithKline PLC
    • 6.1.10 Novo Nordisk AS
    • 6.1.11 Novartis AG
    • 6.1.12 Zealand Pharma AG
    • 6.1.13 AmbioPharm Inc.
    • 6.1.14 Bachem Holding AG
    • 6.1.15 PolyPeptide Group
    • 6.1.16 Sanofi SA
    • 6.1.17 Amylin Pharmaceuticals
    • 6.1.18 CirclePharma Inc.
    • 6.1.19 PeptiDream Inc.
    • 6.1.20 Apitope Technology
    • 6.1.21 Arch NioPartners
    • 6.1.22 Galena Biopharmaceuticals



Have a question?

Jeroen Van Heghe

Manager - EMEA



Christine Sirois

Manager - Americas


Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!